Transactions
Aug. 27, 2002
Cash-and-Debt Buy Boosts Endocare's Marketability
Irvine's Endocare Inc. has agreed to acquire the prostate-treatment business of a Dallas-based urology services company for $11.2 million in cash and debt.
Irvine's Endocare Inc. has agreed to acquire the prostate-treatment business of a Dallas-based urology services company for $11.2 million in cash and debt.
Endocare develops technology to treat prostate cancer and other diseases. The target company, U.S. Medical Development Inc., distributes ...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In